eduKate Singapore

VIEW THIS AS

Auto mode follows the Route Engine until you choose a viewpoint.

YOU ARE HERE

ROUTE CHECK

CONNECTED TO

WHAT NEXT

Use the canonical route for this room, or HELP if you are unsure.

Next useful routeCanonical hubHELP

The Gold Standard of Pharmacovigilance

—

by

eduKate Asia
Three learners review open books together at a classroom table, with stacks of textbooks, stationery and a whiteboard in the bright room.

A medicine appears alongside a sudden increase in reports of dizziness. A headline announces that the treatment causes dizziness in one in fifty users. The data may justify further investigation, but a voluntary reporting system cannot generally supply that incidence denominator—and a report does not itself prove the medicine caused the symptom. The gold standard of pharmacovigilance protects both duties: taking safety concerns seriously and refusing to exaggerate what the evidence establishes.

Pharmacovigilance is the science and work of detecting, assessing, understanding and preventing adverse effects and other problems connected with medicines and vaccines. It extends from receiving individual case reports to evaluating signals, investigating mechanisms and population risk, communicating appropriately and monitoring whether risk controls work. It is a continuing health-system function, not simply a database of complaints.

The World Health Organization defines pharmacovigilance as a continuous safety activity. In Singapore, the HSA professional adverse-event guide updated 28 May 2026 explains what clinicians should report and which details support assessment. The FDA’s 2026 adverse-event monitoring system emphasises that public reports do not establish causality or rates. This guide builds on eduKate’s Pharmacology, Biostatistics and Medical Ethics roots.

Quick information: a safety signal is a question, not a judgment

Record a suspected event, its chronology, product identity and relevant clinical context. Assess duplicates, alternative explanations and completeness. A disproportionate pattern of reports can justify stronger investigation, but reports alone usually cannot show incidence, comparative risk or confirmed causation. Decisions to change labels, monitoring or treatment require appropriately qualified and authorised assessments. For personal symptoms, use clinical care channels and do not alter prescribed medicines based on online report counts.

Chapter index

Worked case one: a reporting odds ratio is not a risk ratio

Imagine a fictional adverse-event database with Drug A: 40 reports mentioning a particular event and 160 reports of other events. For a specified comparison set, Drug B: 20 reports mention the event and 180 reports concern other events. The reporting odds for A are 40 / 160 = 0.25 and for B are 20 / 180 ≈ 0.111. The reporting odds ratio is 0.25 / 0.111 ≈ 2.25.

A reporting odds ratio of 2.25 means that, within these fictional submitted reports and comparison rules, the event occupies a larger fraction for A. It does not mean A causes the event 2.25 times as often in treated patients. The table lacks total exposed people, complete outcome capture and adjustment for differences between users. Duplicates, publicity and indication can distort the pattern. The correct output is a possible signal for review, not a headline about proven danger.

Twenty controls for reliable pharmacovigilance

1. Start with a possible safety problem, not a verdict

Pharmacovigilance is the detection, assessment, understanding and prevention of adverse effects and other medicine-related problems. A clinician may suspect a reaction when a new symptom follows treatment, but timing alone does not prove causation. Define the product, event, time course and clinical context, preserving uncertainty. The WHO pharmacovigilance programme stresses continued monitoring beyond pre-authorisation trials. An effective safety system makes credible concerns visible early without declaring every report a confirmed drug injury.

2. Distinguish adverse events from adverse reactions

An adverse event is an unwanted medical occurrence in temporal association with treatment, without necessarily implying causality. A suspected adverse drug reaction is considered under relevant reporting definitions and regional rules. The terminology can affect case handling, but clinical safety must not wait for perfect wording. Explain whether the information comes from a patient, clinician, sponsor or data source, and whether any causal assessment was made. Avoid writing ’caused by’ in a public summary when the data support only ‘reported after use’.

3. Understand why clinical trials do not detect everything

Pre-authorisation trials have finite duration, eligibility criteria and sample sizes. Rare effects, delayed harms, interactions and events in underrepresented patients may appear later. Post-market experience often involves larger and more varied populations, but it also introduces confounding and incomplete reports. A medicine’s authorisation reflects an assessed benefit-risk balance, not proof of zero risk. The WHO strategy frames ongoing safety monitoring as a health-system activity, including vaccines, biologics and complementary products as applicable.

4. Respect reporting rules for the actual jurisdiction

Singapore’s HSA professional guide updated 28 May 2026 highlights reporting new-product events, serious events and unexpected reactions, with product-specific routes. Industry obligations and clinical trial duties are not necessarily identical to voluntary clinician reporting. The HSA industry guide describes serious-case reporting responsibilities and timelines for companies. Do not generalise an EU or U.S. rule to Singapore. Verify current reporting requirements, product categories and responsibilities before applying them to real practice.

5. Capture useful case-level facts promptly

A meaningful case describes the event, suspect product, time of exposure and onset, patient circumstances and relevant alternatives. HSA lists patient characteristics, reporter contact, product dates and batch information where available, concurrent products and relevant clinical details. Recording a suspected event need not wait until every causal question is solved. However, missing details should remain explicitly missing, and patient privacy should be protected. A source database can only assess what is recorded, making timely follow-up and accurate chronology particularly valuable.

6. Validate identity and prevent duplicate cases

The same event might be reported by a patient, hospital and manufacturer, producing several records if duplicates are not reconciled. Product names, dates, initials and clinical facts may help link possible duplicates under relevant privacy and reporting rules. Never merge distinct events solely because they share a symptom, nor count multiple submissions about one case as independent injuries. Preserve audit trails for duplicate adjudication and corrections. An apparently accelerating signal may partly reflect growing publicity or duplicated reports.

7. Record seriousness without confusing it with intensity

Seriousness is a regulatory concept associated with outcomes such as death, life-threatening events or certain hospitalisations, whereas severity may describe intensity of symptoms. A severe headache may not meet a regulatory serious criterion; a comparatively subtle event can be serious if it causes a qualifying outcome. Use the definitions that govern the actual report, including medically important conditions where relevant. Do not let colloquial wording substitute for a structured, documented determination. Serious events may require urgent clinical action independently of any reporting deadline.

8. Describe exposure timing and dechallenge cautiously

The chronology of treatment and event onset can support or weaken a causal hypothesis. Changes after drug withdrawal or reintroduction may sometimes contribute evidence, but natural disease variation, simultaneous treatments and timing differences can confound interpretation. Do not advise patients to stop or restart a medicine merely to test causality. Deliberate rechallenge may be unsafe or unethical. A safety assessment should use available clinical records and expert judgement rather than demanding an experimental proof from a patient.

9. Consider alternative explanations and co-medications

Underlying disease, infection, recent surgery, other medicines, diet, product quality and measurement error can all contribute to an event. The relevant competing hypotheses vary by case. Assess whether the event is consistent with known pharmacology and whether stronger evidence is available from multiple sources. A temporal association is a necessary element for some suspicions but is not sufficient to prove cause. The correct message to a patient is a qualified review, not an unverified accusation against a medicine.

10. Use harmonised individual-case safety reporting carefully

The ICH E2D(R1) guideline finalised by FDA in March 2026 addresses definitions and management of post-approval individual case safety reports, including increasingly used information sources such as support programmes and social media. A company’s reporting system needs consistent source classification, documented validation and appropriate obligations. A social-media mention may require investigation rather than immediate classification as a complete case. Preserve source context and privacy while following the applicable local implementation of the guideline.

11. Recognise reporting bias and publicity effects

Adverse-event submissions can increase after media coverage, litigation publicity, an updated label or targeted professional education. A declining number can reflect lower use or weaker reporting rather than safer products. Reporting rates differ by country, profession and product age. The FDA AEMS explanation warns that public report counts cannot establish incidence and that submitted observations are not necessarily verified. Always distinguish changes in submitted reports from changes in clinical risk.

12. Never compute clinical incidence from spontaneous reports alone

A case-reporting database generally lacks a reliable denominator of all exposed patients and complete event ascertainment. For example, 20 suspected reports do not mean 20 events among 1,000 exposed people unless a separate valid exposure and outcome study establishes that denominator. The FDA AEMS data limitations explicitly caution against estimating occurrence rates from spontaneous reports. Use well-designed pharmacoepidemiology or other suitable data for incidence or comparative risk estimates.

13. Use disproportionality screening as a signal, not a causal verdict

Measures such as a reporting odds ratio compare the pattern of reported event–drug pairs within an adverse-event database. They can identify combinations worth further review but reflect reporting behaviour, confounding and selection. A large reporting odds ratio does not directly estimate the risk of the event in users and can be unstable for rare report counts. State the event coding, comparison group, data extraction date and uncertainty. Investigate the signal with independent clinical and epidemiologic evidence before describing a causal association.

14. Validate and prioritise credible safety signals

The EU’s signal management framework distinguishes detection, validation, confirmation, prioritisation, assessment and recommendations for action. Confirmation that a signal merits discussion does not imply causal proof. Consider potential severity, preventability, exposure, vulnerable populations and available evidence when prioritising. A rare but serious possible reaction may warrant more urgent assessment than a common mild event. A signal should not be discarded merely because its initial numerical indicator is imperfect.

15. Evaluate benefits and risks together

A safety concern may change how a medicine is labelled, monitored, restricted or used, but decisions depend on the treatment’s benefits and alternatives as well as potential harms. The EMA PRAC description places risk identification, minimisation and communication alongside therapeutic benefit. A product with an important potential reaction may remain appropriate for some conditions under careful guidance. Regulators and qualified clinicians evaluate the relevant evidence; an online report count is not a personal prescribing decision.

16. Design additional studies to test hypotheses

A signal may lead to cohort studies, case-control analyses, registries, targeted clinical review or a trial where ethical and feasible. Study designs need appropriate comparison groups, clear outcome definitions, exposure windows and adjustment for factors that influence treatment and disease. Observational evidence can be biased by confounding by indication: sicker patients may receive a drug more often and also suffer the outcome. State limitations and validate the case definition rather than treating database associations as experimental facts.

17. Keep product quality and medication errors in view

Safety concerns can arise from defective batches, substitution, contamination, misuse or medication processes as well as expected pharmacological action. Which events are reportable under a particular route depends on product and local regulatory rules; do not presume every category is handled identically. Record batch identifiers, administration details and contributing work-system factors when relevant. Separate clinical care of the affected patient from formal notification and product investigation, while ensuring neither task is neglected.

18. Communicate emerging risks without alarming people unnecessarily

An early potential signal should be explained with its uncertainty and practical significance. Say what has been observed, what remains unknown, which authority is evaluating the issue and where current product-specific instructions can be found. Avoid announcing that a medicine ’caused’ an event when causal assessment is incomplete. Equally, avoid concealing important risk information because it is inconvenient. Patients should contact their qualified clinician rather than independently discontinue prescribed treatments after encountering a speculative headline.

19. Measure whether risk-minimisation action works

A safety letter, label change or educational campaign is an intervention whose impact requires evaluation. Check clinician awareness, prescribing changes where appropriate, patient understanding, actual adverse outcomes, unintended undertreatment and unequal access. A fall in reports is insufficient evidence that harm decreased, since reporting may also decline. Define an evaluation window, independent outcome measures and responsible oversight. Be ready to revise risk controls when they fail or introduce new problems.

20. Maintain a transparent, correctable safety system

Audit case completeness, duplicates, assessment steps, timely reporting, data protection, signal decisions and communication. Record who reviewed the evidence and when conclusions changed. Independent scrutiny can reveal coding errors, confounding or missed severe cases. Publication and research datasets require lawful protection of patients and reporters. The gold standard is not a promise of side-effect-free medicines; it is a continuous and accountable system for learning from suspected harms while protecting the benefits of care.

Worked case two: twenty reports without known exposure

A fictional national database receives 20 suspected cases concerning one medicine in a year. An observer divides twenty by a sales estimate of 2,000 packs and announces a 1% incidence. That calculation is invalid: packs are not necessarily people, events may be underreported, a person can submit or generate multiple reports, and the number of exposed individuals is unknown. Treatment duration and patient characteristics also vary.

The FDA AEMS data limitations explicitly caution against treating spontaneous counts as incidence. A proper risk estimate requires an appropriate study population, exposure definition, outcome ascertainment and comparison. The twenty records remain valuable for signal detection and follow-up without supporting the invented 1% claim.

Third worked case: a risk letter that changes reporting, not harm

Suppose a fictional safety notice encourages staff to report an uncommon symptom. Submitted reports rise from five to fifteen during otherwise comparable periods. The numerator has tripled, but that alone cannot show the physiological risk tripled. Increased awareness, reporting access and publicity may account for some or all of the change. The responsible assessment examines actual patient outcomes, the exposure population, changes in data collection and independent evidence.

Likewise, a decline in submitted reports after a warning does not by itself prove a successful risk-minimisation intervention. Evaluate how patients and professionals behave and whether clinically meaningful events changed under a suitably designed review.

Practical safety-system audit

  • Is the product and the clinical event described precisely?
  • Do onset, treatment timing and important co-medications appear in the record?
  • Was report seriousness assessed under applicable local definitions?
  • Were duplicate submissions checked without merging distinct patients?
  • Is the data source a spontaneous report, trial, registry or observational study?
  • Are possible alternative causes and reporting biases considered?
  • Does the analysis avoid calculating incidence from report counts alone?
  • Were potential signals validated, prioritised and evaluated appropriately?
  • Are patients informed of current actionable guidance without exaggerated certainty?
  • Have risk-minimisation interventions been evaluated against real outcomes?
  • Can the case history, communications and later corrections be audited?

Frequently asked questions

What is pharmacovigilance?

The science and activities used to detect, assess, understand and prevent adverse effects and other medicine-related problems.

Is an adverse-event report proof a drug caused harm?

No. Reports record suspicions or observations that require investigation; the event may have other causes.

What is the difference between an adverse event and a reaction?

An event need not have a causal link; a suspected reaction involves a causal assessment or suspicion under relevant conventions.

Why monitor a medicine after approval?

Large, varied populations and longer exposure can reveal rare, delayed or context-dependent effects absent from earlier trials.

What does a pharmacovigilance signal mean?

Information suggesting a possible new or changed safety association that warrants analysis; it is not a causal verdict.

Can public reports show the percentage of users harmed?

Not alone. Voluntary-report systems generally lack complete exposure denominators and event ascertainment.

What is a reporting odds ratio?

A comparison of event-report proportions within a reporting database; it flags patterns, not true incidence or proven risk.

How do healthcare professionals report in Singapore?

Follow the current HSA product-specific and professional adverse-event reporting guidance, including serious and unexpected events as applicable.

What is the FDA AEMS dashboard?

A U.S. FDA consolidated adverse-event reporting platform whose records need careful interpretation and cannot establish incidence or causality by themselves.

Should someone stop a prescribed medicine after reading a signal?

Do not change treatment solely from an educational signal discussion; discuss concerns promptly with the responsible clinician or pharmacist.

What is risk minimisation?

Measures aimed at reducing a medicine-related risk through appropriate information, monitoring, restrictions or system changes.

What makes a safety programme credible?

Complete, traceable cases; timely lawful reporting; independent signal assessment; fair risk communication; and evaluation of actual results.

Sources, regulation and limits

All report counts, medicines and event examples in this article are fictional. Regulatory reporting requirements and clinical actions vary by jurisdiction, product and role; use the current local rule. This is not a treatment instruction, adverse reaction diagnosis, claim about any real product’s risk, or substitute for qualified medical advice. The Gold Standard is an editorial evidence framework, not an official medicine-safety certification.